Aarhus, Denmark, 5 September 2006 ... Borean Pharma ApS, the Danish biopharmaceutical and protein engineering company, today announced that Associate Professor Hans Christian Thøgersen, the founder and CSO of Borean, has received a prize from Science Park Aarhus in recognition of Borean’s success as a company.

To commemorate the 20th anniversary of the foundation of Aarhus Science Park in 2006, it will grant an award of 100 000 DKK (13000 Euro) annually to the person, company or institute that made a strong effort to link commerce and science. Professor Thøgersen is one of two individuals who won this inaugural prize. The award reflects the formidable achievement in launching Borean Pharma based on studies of the C-Type lectin, Tetranectin performed by him, the co-founder Michael Etzerodt, and Thor Las Holtet.

Hans Christian Thøgersen first came to Science Park Aarhus in 1989 as a lecturer in the Institute of Molecular Biology. His research over the next decade led to the breakthroughs in protein engineering that formed the basis of Borean Pharma, which he and Michael Etzerodt founded in 2001. Since then Borean Pharma has used this technology to discover and develop engineered protein therapeutics and recently announced an eye-catching deal with Roche over the licensing of Borean’s lead product, Apo-AI, a protein for the treatment of atherosclerosis.

“I am delighted to have won this award,” commented Hans Christian Thøgersen “I am proud of what we have achieved at Aarhus University and Borean Pharma and pleased that it has been recognised.”

- ends -

About Borean Pharma: www.boreanpharma.com

Borean Pharma was established with the objective to develop a new generation of pharmaceutical protein products. The company's competitive advantage lies in its proprietary technology, enabling it to develop a new generation of highly efficacious compounds and antibody analogues that can be produced in E. coli. The ease of production addresses a major shortcoming of monoclonal antibodies. Borean Pharma believes that it can unleash the true potential of biopharmaceuticals by providing efficacious and cost-effective protein-based antibody analogues. The Company recently licensed its lead for atherosclerosis, Apo-AI, to Roche and, among other programmes, is also developing a TNFa antagonist for Rheumatoid Arthritis. Borean was founded in 2001 as a spin-off from Aarhus University The firm has been backed by an investment syndicate consisting of ABN Amro AMC, Aravis Venture, Bankinvest, Incuba and Novi. For further information please visit the website at www.boreanpharma.com

Contact: